Percheron Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Percheron Therapeutics CEO'su James Garner, Aug2023 tarihinde atandı, in görev süresi 1.42 yıldır. in toplam yıllık tazminatı A$ 824.68K olup, şirket hissesi ve opsiyonları dahil olmak üzere 52.7% maaş ve 47.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.28% ine doğrudan sahiptir ve bu hisseler A$ 21.00K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.4 yıl ve 3.3 yıldır.

Anahtar bilgiler

James Garner

İcra Kurulu Başkanı

AU$824.7k

Toplam tazminat

CEO maaş yüzdesi	52.7%
CEO görev süresi	1.4yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	1.4yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

CEO Tazminat Analizi

James Garner'un ücretlendirmesi Percheron Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$825k	AU$434k	-AU$12m
Mar 31 2024	n/a	n/a	-AU$11m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$11m
Jun 30 2023	AU$34k	n/a	-AU$11m

Tazminat ve Piyasa: James 'nin toplam tazminatı ($USD 512.67K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 283.29K ).

Tazminat ve Kazançlar: James şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

James Garner (51 yo)

1.4yrs

Görev süresi

AU$824,684

Tazminat

Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, serves as Non-Executive Director at Percheron Therapeutics Limited (formerly known as Antisense Therapeutics Limited) since May 08, 2023 and has been its...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Garner	CEO, MD & Director	1.4yrs	AU$824.68k	0.28% A$ 21.0k
Deborah Ambrosini	Company Secretary & CFO	less than a year	AU$324.32k	Veri yok
Anthony Filippis	Chief Operating Officer	2yrs	AU$596.05k	Veri yok
Cathryn Clary	Chief Medical Advisor	no data	Veri yok	Veri yok

1.4yrs

Ortalama Görev Süresi

Deneyimli Yönetim: PER 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.4 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Garner	CEO, MD & Director	1.7yrs	AU$824.68k	0.28% A$ 21.0k
Ben Price	Independent Non-Executive Director	3.3yrs	AU$113.77k	0.094% A$ 7.0k
Charmaine Gittleson	Independent Non-Executive Chair	3.8yrs	AU$220.29k	0.069% A$ 5.1k

3.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: PER 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/02 09:05
Gün Sonu Hisse Fiyatı	2025/01/02 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2024/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Percheron Therapeutics Limited 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
John Hester	Bell Potter
Iain Wilkie	Morgans Financial Limited
Dr Storey	Wilsons Advisory and Stockbroking Ltd.

Percheron Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Less than half of directors are independent

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Recent updates

Consensus revenue estimates decrease by 34%

Price target decreased by 7.1% to AU$0.20

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to AU$0.031 loss

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

New major risk - Financial position

Consensus EPS estimates upgraded to AU$0.034 loss

Forecast to breakeven in 2027

Consensus revenue estimates decrease by 40%

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

CEO Tazminat Analizi

CEO

Görev süresi